NEW DELHI, Sep. 18, 2022 (TBINN)
Two COVID-19 anti-body treatments are no longer recommended by the World Health Organisation because OMICRON and its sub-variants have likely rendered them obsolete, according to a revised guideline published in the British Medical Journal.
In the same guideline update, W.H.O. makes a conditional recommendation for the use of the anti-viral drug Remdesivir in patients with severe COVID-19 and a conditional recommendation against its use in patients with critical disease.
The W.H.O. Guideline Development Group of international experts noted that anti-body drugs Sotrovimab and Casirivimab-imdevimab are not recommended for patients with COVID-19.